The Israeli Ministry of Health has approved Anadis' (ASX:ANX) clinical protocol, clearing the way for trials of its mucositis treatment to begin within a month.

Mucostisis is a significant side effect of cancer therapy, experienced by between 20 and 100 per cent of patients, depending on the type of cancer and treatment.

Effects include painful mouth ulcerations and severe gastrointestinal symptoms.

The Anadis drug contains a unique formulation of Anadis' immune milk-derived anti LPS antibodies as well as other bioactives, and will be delivered using Anadis' oral delivery technology.

Anadis was recently awarded a grant from Vistech to help fund the drug development program.